MAP2K7 and Miyoshi myopathy: Aiming to identify alternative treatment options for primary and relapsed MM we recently showed activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor with a 2nd generation hexameric TRAIL-receptor agonist (IZI1551 [20, 21]), to be superior in subjecting mutBRAF MM cells to cell death compared to combined mutBRAF/MEK inhibition [22].